Group 1 - The core viewpoint of the article is that Changshan Pharmaceutical acknowledges the influence of various factors on its stock price fluctuations in the secondary market and emphasizes its commitment to improving operational quality and advancing innovative drug review processes to enhance intrinsic value [2] Group 2 - The company is actively engaging with investors through platforms to address concerns and provide updates on its strategic initiatives [2] - Changshan Pharmaceutical is focused on continuous improvement in its business operations and innovation efforts [2]

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, CXHS2400019, and is prepared for potential commercialization while addressing industry competition and operational pressures [1]. Group 1: Drug Approval and Commercialization - The registration review for the innovative drug, CXHS2400019, is currently in progress, with the specific timeline dependent on the National Medical Products Administration (NMPA) [1]. - The company maintains good communication with clinical institutions involved in the research, which lays a solid foundation for future commercialization efforts [1]. - The company is open to collaborating with experienced and capable teams for the promotion of the drug [1]. Group 2: Business Strategy and Financial Performance - The company is actively expanding its overseas sales and enhancing its Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) operations to reduce costs and improve efficiency [1]. - The company reported its first loss in 2025, indicating a challenging competitive environment in the pharmaceutical sector [1]. - The management is focused on maintaining shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1].